Scholarlink

Background <p>Antibodies to SARS-CoV-2 are essential for protection or reduction in severity of subsequent disease. We studied antibody responses to spike protein receptor-binding domain (S1-RBD) and nucleocapsid (N) in a population-based sample of COVID-19 cases in Costa Rica.</p> Methods <p>As part of the RESPIRA study, we selected an age-stratified random sample of PCR-confirmed COVID-19 cases diagnosed from March 2020 to July 2021. Antibodies were determined with multiplex serology in 794 unvaccinated subjects diagnosed 3&#xa0;days to 17&#xa0;months before recruitment to investigate immune response to natural infection. In addition, neutralizing antibodies were&#xa0;determined in 136 randomly selected participants. We estimated antibody positivity and GMTs by time since diagnosis and explored determinants using multivariate regression.</p> Results <p>Most participants tested 15–29&#xa0;days after PCR diagnosis were seropositive for N (90%) and S1-RBD antibodies (96%) and had the highest GMTs for both antibodies. Only 42% of subjects tested one year after infection were seropositive for N antibodies, compared to 97% for S1-RBD. GMTs for neutralizing antibodies peaked 15–89&#xa0;days after infection and declined but remained positive for 95% of subjects thereafter. In multivariate models, antibodies were significantly higher among men and increased with age and severity of the clinical presentation. The correlation of multiplex and neutralizing antibodies was high (0.72 [95% CI = 0.63–0.79]) and stronger among women.</p> Conclusions <p>A robust immune response against N and S1-RBD is elicited by COVID-19 a few days after infection. While S1-RBD antibodies are present after &gt; 1&#xa0;year, N antibodies decline significantly. Antibody levels are higher in men and increase with age and severity of disease. The different immune response patterns by sex warrant further investigation.</p> Trial registration <p>RESPIRA Study ClinicalTrials.gov ID: NCT04537338 (3 September 2020).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Time course and determinants of the antibody response to SARS-CoV-2 in Costa Rica: the RESPIRA study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月18日

查看全文
  • Rolando Herrero,
  • Romain Fantin,
  • Viviana Loría,
  • Amada Aparicio,
  • D. Rebecca Prevots,
  • Michael Zúñiga,
  • Roy Wong,
  • Melvin Morera,
  • Julia Butt,
  • Marco Binder,
  • Arturo Abdelnour,
  • Alejandro Calderón,
  • Roberto Castro,
  • Bernal Cortes,
  • Rebeca Ocampo,
  • Juan Carlos Vanegas,
  • Mitchell H. Gail,
  • Ruth M. Pfeiffer,
  • Julia Flock,
  • Kim Remans,
  • Lukas Eberhardt,
  • Soheil Rastgou,
  • Vladimir Magalhaes,
  • Carolina Porras,
  • Allan Hildesheim,
  • Tim Waterboer

摘要

Background

Antibodies to SARS-CoV-2 are essential for protection or reduction in severity of subsequent disease. We studied antibody responses to spike protein receptor-binding domain (S1-RBD) and nucleocapsid (N) in a population-based sample of COVID-19 cases in Costa Rica.

Methods

As part of the RESPIRA study, we selected an age-stratified random sample of PCR-confirmed COVID-19 cases diagnosed from March 2020 to July 2021. Antibodies were determined with multiplex serology in 794 unvaccinated subjects diagnosed 3 days to 17 months before recruitment to investigate immune response to natural infection. In addition, neutralizing antibodies were determined in 136 randomly selected participants. We estimated antibody positivity and GMTs by time since diagnosis and explored determinants using multivariate regression.

Results

Most participants tested 15–29 days after PCR diagnosis were seropositive for N (90%) and S1-RBD antibodies (96%) and had the highest GMTs for both antibodies. Only 42% of subjects tested one year after infection were seropositive for N antibodies, compared to 97% for S1-RBD. GMTs for neutralizing antibodies peaked 15–89 days after infection and declined but remained positive for 95% of subjects thereafter. In multivariate models, antibodies were significantly higher among men and increased with age and severity of the clinical presentation. The correlation of multiplex and neutralizing antibodies was high (0.72 [95% CI = 0.63–0.79]) and stronger among women.

Conclusions

A robust immune response against N and S1-RBD is elicited by COVID-19 a few days after infection. While S1-RBD antibodies are present after > 1 year, N antibodies decline significantly. Antibody levels are higher in men and increase with age and severity of disease. The different immune response patterns by sex warrant further investigation.

Trial registration

RESPIRA Study ClinicalTrials.gov ID: NCT04537338 (3 September 2020).